

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 22-6-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 21-4-2007 TO BE PUBLISHED ON 23-6-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

423/2007	<u>16-04-2007</u> 1. Labopharm Inc., Canada 2. Labopharm Europe Limited Ireland 3. Labopharm (Barbados) Limited, Barbados (Priority 11-9-06 USA)	“Trazodone composition for once a day administration”
424/2007	Merck and Co., Inc. USA (Priority 25-4-06 US)	“ Inhibitors of checkpoint Kinases”
425/2007	Alba Therapeutics Corporation, USA (Priority 19-4-06 US)	“ Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents”
426/2007	Abbott GmbH & Co., KG Germany (Priority 19-4-06 US)	“ Heterocyclic compounds suitable for treating disorder that respond to modulation of the serotonin 5HT6 receptor”
427/2007	<u>17-4-2007</u> AstraZeneca AB, Sweden (Priority 18-4-06 USA)	“ Therapeutic compounds”
428/2007	Honda Motor Co., Ltd Japan (Priority 23-6-06 Japan)	“ Internal combustion engine for vehicle”
429/2007	Boehringer Ingelheim International GmbH, Germany, (Priority 19-4-06 Europe)	“ Dihydrothienopyrimidines for the treatment of inflammatory diseases”
430/2007	SmithKline Beecham Corporation, USA (Priority 17-4-06 US)	“ Chemical compounds”
431/2007	SmithKline Beecham Corporation, USA (Priority 17-4-4-2006 USA)	“Chemical Compounds”
432/2007	SmithKline Beecham Corporation, USA	“Chemical Compounds”

	(Priority 17-4-4-2006 USA)	
433/2007	Wyeth, USA (Priority 18-4-06 US)	“ Chromane and chromane derivatives and uses thereof”
434/2007	Wyeth, USA (Priority 18-4-06 US)	“ Benzodioxamane and benzodioxolane derivatives and uses thereof”
435/2007	AstraZeneca AB, Sweden (Priority 27-4-06 US)	“Chemical Compounds”
436/2007	Janssen Pharmaceutica N.V. Belgium (Priority 19-4-06 Europe)	“ Trisubstituted 1, 2, 4-Triazoles”
437/2007	Bristol-Myers Squibb Company, USA (Priority 17-4-06 US)	“ NK-1 and serotonin transporter inhibitors”
438/2007	Aventis Pharmaceuticals Inc. USA (Priority 26-10-01 France) Divisional	“Benzimidazoles”
439/2007	<u>18-4-2007</u> Novartis AG, Switzerland (Priority 21-4-06 GB)	“ Organic Compounds”
440/2007	Novartis AG, Switzerland (Priority 21-4-06 GB)	“ Organic Compounds”
441/2007	Emotive Communication Inc., USA (Priority 19-4-06 US)	“ System and methodology for peer-to-peer-to-peer voice communication employing a pushed multimedia announcement”
442/2007	Ono Pharmaceutical Co., Ltd. Japan Divisional	“ Pharmaceutical composition comprising (2R)-2-propyloctanoic acid salts as an active ingredient”
443/2007	Sciclone Pharmaceuticals, Inc. USA (Priority 20-4-06 US)	“ Treatment of melanoma”
444/2007	Glaxo Group Limited, UK (Priority 20-4-06 GB)	“ Novel Compounds”
445/2007	Glaxo Group Limited, UK	“ Compounds”

(Priority 20-4-06 GB)

446/2007	<p><u>19-4-2007</u> Pfizer Products Inc. USA (Priority 21-4-06 USA)</p>	“ Pyridine [3, 4-b] pyrazinones”
447/2007	<p>Pfizer Products Inc. USA (Priority 20-4-06 USA)</p>	“ Fused phenyl amido heterocyclic compounds”
448/2007	<p>ESCO Corporation, USA (Priority 24-4-06 US)</p>	“ Wear Assembly”
449/2007	<p>Banyu Pharmaceutical Co., Ltd. Japan (Priority 27-4-06 Japan)</p>	“ Dihydropyrazolopyrimidinone derivatives”
450/2007	<p>E.I. DU Pont DE Nemours and Co., USA (Priority 12-5-06 US)</p>	“ Herbicidal mixture”
451/2007	<p>Novartis AG, Switzerland (Priority 19-4-06 US)</p>	“ 6-O substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling”
452/2007	<p><u>20-4-2007</u> 1. Novartis AG, Switzerland 2. XOMA Technology Ltd, USA (Priority 21-4-06 US)</p>	“ Antagonist anti-cd40 antibody pharmaceutical compositions”
453/2007	<p>Axesstel, Inc., USA (Priority 20-4-06 US)</p>	“ Communication terminal using Ethernet interface”
454/2007	<p>Axesstel, Inc., USA (Priority 20-4-06 US)</p>	“ Communication management using Ethernet interface”
455/2007	<p><u>21-4-2007</u> Warner-Lambert Company, USA (Priority 31-7-01 US) Divisional</p>	“ Pharmaceutical composition comprising amlodipine and atorvastatin salt”
456/2007	<p>1. Cellzome (UK) Ltd. UK 2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., USA (Priority 21-4-06 Europe)</p>	“ Triaryl compounds and derivatives thereof”

457/2007	1. Cellzome (UK) Ltd. UK 2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C., USA (Priority 21-4-06 Europe)	“ Substituted biphenyl carboxylic acids and derivatives thereof”
458/2007	SmithKline Beecham Corporation, USA (Priority 21-4-06 US)	“ IL-8 receptor antagonists”

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139262	Pfizer Products Inc. USA	497/1999
139263	Pfizer Products Inc. USA	867/1999
139264	Novartis AG, Switzerland	849/2001
139265	Pfizer Products Inc. USA	297/2005

(Mrs. Yasmeen Abbasi)

Controller of Patents & Designs

Tel: 9215488